Dr Michelle Lawson

All publications

Journal articles

• Tazzyman S, Stewart GR, Yeomans J, Linford A, Lath D, Conner J, Muthana M, Chantry AD & Lawson MA (2023) HSV1716 prevents myeloma cell regrowth when combined with bortezomib in vitro and significantly reduces systemic tumor growth in mouse models. Viruses, 15(3).
• Diaz-delCastillo M, Nemler T, Thygesen DM, Chávez-Saldaña NA, Vázquez-Mora JA, Palasca O, Juhl L, Evans H, Andrews RE, Mandal A , Chantry AD et al (2022) P-133: Myeloma-induced bone pain: lessons learnt from a localized, immunocompetent mouse model. Clinical Lymphoma Myeloma and Leukemia, 22, S108-S108.
• Stewart G, Chantry A & Lawson M (2021) The use of oncolytic viruses in the treatment of multiple myeloma. Cancers, 13(22).
• Tattersall L, Shah KM, Lath DL, Singh A, Down JM, De Marchi E, Williamson A, Di Virgilio F, Heymann D, Adinolfi E , Fraser WD et al (2021) The P2RX7B splice variant modulates osteosarcoma cell behaviour and metastatic properties. Journal of Bone Oncology, 31, 100398-100398.
• Andrews RE, Brown JE, Lawson MA & Chantry AD (2021) Myeloma bone disease : the osteoblast in the spotlight. Journal of Clinical Medicine, 10(17).
• Müller LME, Migneco G, Scott GB, Down J, King S, Askar B, Jennings V, Oyajobi B, Scott K, West E , Ralph C et al (2021) Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. Journal for ImmunoTherapy of Cancer, 9(3).
• Ottewell PD & Lawson MA (2021) Advances in murine models of breast cancer bone disease. Journal of Cancer Metastasis and Treatment, 7.
• Diaz-delCastillo M, Chantry AD, Lawson MA & Heegaard A-M (2021) Multiple myeloma—A painful disease of the bone marrow. Seminars in Cell & Developmental Biology, 112, 49-58.
• Marino S, Carrasco G, Li B, Shah KM, Lath DL, Sophocleous A, Lawson MA & Idris AI (2020) JZL184, a monoacylglycerol lipase inhibitor, induces bone loss in a multiple myeloma model of immunocompetent mice. Calcified Tissue International, 107(1), 72-85.
• Crawford LJ, Campbell DC, Morgan JJ, Lawson MA, Down JM, Chauhan D, McAvera RM, Morris TC, Hamilton C, Krishnan A , Rajalingam K et al (2020) The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma. Oncogene, 39(27), 5001-5014.
• Diaz-delCastillo M, Kamstrup D, Olsen RB, Hansen RB, Pembridge T, Simanskaite B, Jimenez-Andrade JM, Lawson MA & Heegaard A-M (2020) Differential pain-related behaviors and bone disease in immunocompetent mouse models of myeloma. JBMR Plus, 4(2).
• Green AC, Lath D, Hudson K, Walkley B, Down JM, Owen R, Evans HR, Paton‐Hough J, Reilly GC, Lawson MA & Chantry AD (2019) TGFβ Inhibition Stimulates Collagen Maturation to Enhance Bone Repair and Fracture Resistance in a Murine Myeloma Model. Journal of Bone and Mineral Research, 34(12), 2311-2326.
• Faraahi Z, Baud'huin M, Croucher PI, Eaton C & Lawson MA (2019) Corrigendum to “Sostdc1: A soluble BMP and Wnt antagonist that is induced by the interaction between myeloma cells and osteoblast lineage cells” [Bone 122 (May 2019) 82–92]. Bone, 124, 166-166.
• Faraahi Z, Baud'huin M, Croucher PI, Eaton C & Lawson MA (2019) Sostdc1: A soluble BMP and Wnt antagonist that is induced by the interaction between myeloma cells and osteoblast lineage cells. Bone, 122, 82-92.
• Stewart GR, Tazzyman S, Lath D, Down J, Snowden JA, Lawson M, Muthana M & Chantry AD (2018) Myeloma-Specific Oncolytic Adenovirus Induces Significant Tumour Oncolysis In Vitro and In Vivo and Prevents Cell Line Regrowth. Blood, 132(Supplement 1), 3213-3213.
• Paton-Hough J, Tazzyman S, Evans H, Lath D, Down JM, Green AC, Snowden JA, Chantry AD & Lawson MA (2018) Preventing and repairing myeloma bone disease by combining conventional antiresorptive treatment with a bone anabolic agent in murine models. Journal of Bone and Mineral Research.
• Lath DL, Buckle CH, Evans HR, Fisher M, Down JM, Lawson MA & Chantry AD (2018) ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo.. PLoS One, 13(6).
• Ring ES, Lawson MA, Snowden JA, Jolley I & Chantry AD (2018) New agents in the Treatment of Myeloma Bone Disease. Calcified Tissue International, 102(2), 196-209. View this article in WRRO
• Lawson MA, Ebetino FH, Mazur A, Chantry AD, Paton-Hough J, Evans HR, Lath D, Tsoumpra MK, Lundy MW, Dobson RLM , Quijano M et al (2017) The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1‐Fluoro‐2‐(Imidazo‐[1,2‐α]Pyridin‐3‐yl)‐Ethyl‐Bisphosphonate). Journal of Bone and Mineral Research, 32(9), 1860-1869.
• Chinnaiya K, Lawson MA, Thomas S, Haider M-T, Down J, Chantry AD, Hughes D, Green A, Sayers JR, Snowden JA & Zeidler MP (2017) Low-dose methotrexate in myeloproliferative neoplasm models.. Haematologica, 102, e336-e339.
• Lawson M, Chantry A, Paton-Hough J, Evans H, Lath D, Tsoumpra M, Lundy M, Dobson R, Quijano M, Kwaasi A , Dunford J et al (2016) The pharmacological profile of a novel highly potent bisphosphonate, OX14 (1-fluoro-2-(imidazo-[1,2 alpha]pyridin-3-yl)ethyl-bisphosphonate), with reduced bone affinity, which is as effective as zoledronate in the treatment of myeloma bone disease in JJN3-NOD/SCID-[gamma] mice. Bone Abstracts.
• Evans HR, Karmakharm T, Lawson MA, Walker RE, Harris W, Fellows C, Huggins ID, Richmond P & Chantry AD (2016) Osteolytica: An automated image analysis software package that rapidly measures cancer-induced osteolytic lesions in in vivo models with greater reproducibility compared to other commonly used methods. Bone, 83, 9-16.
• Lawson MA, McDonald MM, Kovacic N, Hua Khoo W, Terry RL, Down J, Kaplan W, Paton-Hough J, Fellows C, Pettitt JA , Neil Dear T et al (2015) Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nature Communications, 6(1), ---.
• Wang N, Docherty F, Brown HK, Reeves K, Fowles A, Lawson M, Ottewell PD, Holen I, Croucher PI & Eaton CL (2015) Mitotic quiescence, but not unique “stemness,” marks the phenotype of bone metastasis-initiating cells in prostate cancer. The FASEB Journal, 29(8), 3141-3150. View this article in WRRO
• Paton-Hough J, Chantry AD & Lawson MA (2015) A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease. Bone, 77, 57-68.
• Walker RE, Lawson MA, Buckle CH, Snowden JA & Chantry AD (2014) Myeloma bone disease: pathogenesis, current treatments and future targets. British Medical Bulletin, 111(1), 117-138.
• Buckle C, Faraahi Z, Lawson M, Eaton C, Vanderkerken K & Croucher P (2013) A novel antagonist of the canonical Wnt-signalling pathway, Sostdc1, is expressed in experimental models of myeloma and suppresses bone formation. Bone Abstracts.
• Vitovski S, Chantry AD, Lawson MA & Croucher PI (2012) Targeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo.. PLoS One, 7(5), e35830. View this article in WRRO
• Buckle CH, De Leenheer E, Lawson MA, Yong K, Rabin N, Perry M, Vanderkerken K & Croucher PI (2012) Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.. PLoS One, 7(8), e41127. View this article in WRRO
• Lawson MA, Ashcroft J & Croucher PI (2010) Bisphosphonate therapy in the treatment of multiple myeloma.. Curr Pharm Des, 16(27), 3028-3036.
• Bassett JHD, Boyde A, Howell PGT, Bassett RH, Galliford TM, Archanco M, Evans H, Lawson MA, Croucher P, Germain DLS , Galton VA et al (2010) Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts. P NATL ACAD SCI USA, 107(16), 7604-7609.
• Buckle CH, Neville-Webbe HL, Croucher PI & Lawson MA (2010) Targeting RANK/RANKL in the treatment of solid tumours and myeloma.. Curr Pharm Des, 16(11), 1272-1283.
• Lawson MA, Xia Z, Barnett BL, Triffitt JT, Phipps RJ, Dunford JE, Locklin RM, Ebetino FH & Russell RGG (2010) Differences between bisphosphonates in binding affinities for hydroxyapatite. Journal of Biomedical Materials Research Part B: Applied Biomaterials, 92B(1), 149-155.
• Powell F, Lawson M, Rothwell L & Kaiser P (2009) Development of reagents to study the turkey's immune response: Identification and molecular cloning of turkey CD4, CD8α and CD28. Developmental & Comparative Immunology, 33(4), 540-546.
• Lawson MA, Coulton L, Ebetino FH, Vanderkerken K & Croucher PI (2008) Geranylgeranyl transferase type II inhibition prevents myeloma bone disease.. Biochem Biophys Res Commun, 377(2), 453-457.
• Vanderkerken K, Medicherla S, Coulton L, De Raeve H, Willems A, Lawson M, Van Camp B, Protter AA, Higgins LS, Menu E & Croucher PI (2007) Inhibition of p38  Mitogen-Activated Protein Kinase Prevents the Development of Osteolytic Bone Disease, Reduces Tumor Burden, and Increases Survival in Murine Models of Multiple Myeloma. Cancer Research, 67(10), 4572-4577.
• Lawson MA, Xia Z, Triffitt JT, Ebetino FH, Phipps RJ & Russell RGG (2006) Refining the use of hydroxyapatite column chromatography to reveal differences in relative binding affinities of bisphosphonates. Bone, 38(3), 55.
• Xia Z, Lawson MA, Triffitt JT, Ebetino FH, McKenna CE, Marma M, Kashimirov B & Russell RGG (2006) Substitution of the R1 hydroxyl and C1 phosphate of risedronate produces differences in elution profiles on hydroxyapatite ceramic chromatographic columns. Bone, 38(3), 63-64.
• Barralet JE, Wang L, Lawson M, Triffitt JT, Cooper PR & Shelton RM (2005) Comparison of bone marrow cell growth on 2D and 3D alginate hydrogels. Journal of Materials Science: Materials in Medicine, 16(6), 515-519.
• Lawson MA, Barralet JE, Wang L, Shelton RM & Triffitt JT (2004) Adhesion and growth of bone marrow stromal cells on modified alginate hydrogels. Tissue Engineering, 10(9-10), 1480-1491.
• Lawson MA, Barralet JE, Wang L, Shelton RM & Triffitt JT (2004) Adhesion and Growth of Bone Marrow Stromal Cells on Modified Alginate Hydrogels. Tissue Engineering, 10(9), 1480-1491.
• Wang L, Shelton RM, Cooper PR, Lawson M, Triffitt JT & Barralet JE (2003) Evaluation of sodium alginate for bone marrow cell tissue engineering. Biomaterials, 24(20), 3475-3481.
• Vanrompay D, Cox E, Kaiser P, Lawson S, Van Loock M, Volckaert G & Goddeeris B (2001) Protection of turkeys against Chlamydophila psittaci challenge by parenteral and mucosal inoculations and the effect of turkey interferon-gamma on genetic immunization. Immunology, 103(1), 106-112.
• Lawson S, Rothwell L, Lambrecht B, Howes K, Venugopal K & Kaiser P (2001) Turkey and chicken interferon-γ, which share high sequence identity, are biologically cross-reactive. Developmental & Comparative Immunology, 25(1), 69-82.
• Lawson S, Rothwell L & Kaiser P (2000) Turkey and Chicken Interleukin-2 Cross-React inIn VitroProliferation Assays Despite Limited Amino Acid Sequence Identity. Journal of Interferon & Cytokine Research, 20(2), 161-170.
• Diaz-delCastillo M, Palasca O, Nemler TT, Thygesen DM, Chávez-Saldaña NA, Vázquez-Mora JA, Ponce Gomez LY, Jensen LJ, Evans H, Andrews RE , Mandal A et al () Metastatic infiltration of nervous tissue and periosteal nerve sprouting in multiple myeloma induced bone pain in mice and human. The Journal of Neuroscience.
• Tippett VL, Tattersall L, Ab Latif NB, Shah KM, Lawson MA & Gartland A () The strategy and clinical relevance of in vitro models of MAP resistance in osteosarcoma: a systematic review. Oncogene.
• Lawson MA, Paton-Hough JM, Evans HR, Walker RE, Harris W, Ratnabalan D, Snowden JA & Chantry AD () NOD/SCID-GAMMA Mice Are an Ideal Strain to Assess the Efficacy of Therapeutic Agents Used in the Treatment of Myeloma Bone Disease. PLOS ONE, 10(3), e0119546-e0119546.
• Legge CJ, Colley HE, Lawson MA & Rawlings AE () Targeted magnetic nanoparticle hyperthermia for the treatment of oral cancer. Journal of Oral Pathology & Medicine. View this article in WRRO

Chapters

• Holen I, Saleh L, Ottewell PD & Lawson MA (2022) In vivo models used in studies of bone metastases, Bone Cancer (pp. 35-53). Elsevier
• Edwards CM & Lawson MA (2022) Biological relationship between bone and myeloma cells, Bone Cancer (pp. 1005-1017). Elsevier
• Green AC, Andrews RE & Lawson MA (2020) Role of The Osteoclast in Cancer, Encyclopedia of Bone Biology (pp. 180-200). Elsevier
• Russell RGG, Tsoumpra MK, Lawson MA, Chantry AD, Ebetino FH & Pazianas M (2016) Antiresorptives, The Duration and Safety of Osteoporosis Treatment (pp. 17-36). Springer International Publishing
• Holen I & Lawson MA (2015) In vivo models used in studies of bone metastases, Bone Cancer (pp. 503-518). Elsevier
• Alix-Panabieres C, Arlt MJE, Bataille R, Bedard G, Berthold DR, Bianco P, Blanchard F, Blay J-Y, Bolton D, Bolzoni M , Born W et al (2015) List of Contributors, Bone Cancer (pp. xi-xv). Elsevier
• Holen I & Lawson MA (2015) In vivo models used in studies of bone metastases, Bone Cancer: Primary Bone Cancers and Bone Metastases: Second Edition (pp. 503-518).
• Holen I & Lawson MA (2010) In vivo Models Used in Studies of Bone Metastases, Bone Cancer (pp. 347-363). Elsevier
• Ando K, Arslandemir C, Bell WC, Berdal A, Berthold D, Bhat BM, Bhat RA, Bhattacharyya S, Billiard J, Blanchard F , Bodine PVN et al (2010) List of Contributors, Bone Cancer (pp. xi-xv). Elsevier
• Holen I & Lawson MA (2010) In vivo models used in studies of bone metastases, Bone Cancer (pp. 347-363).

Conference proceedings papers

• Diaz-DelCastillo M, Nemler T, Thygesen DM, Chavez-Saldana NA, Vazquez-Mora JA, Palasca O, Juhl L, Evans H, Andrews RE, Mandal A , Chantry AD et al (2023) Mechanisms of Bone Pain in Multiple Myeloma: Involvement of Periosteal Bone Sprouting. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 38 (pp 55-56)
• Diaz-delCastillo M, Nemler T, Thygesen DM, Chavez-Saldana NA, Vazquez-Mora JA, Palasca O, Juhl L, Evans H, Andrews RE, Mandal A , Chantry AD et al (2022) Myeloma-induced bone pain: lessons learnt from a localized, immunocompetent mouse model. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, Vol. 22 (pp S108-S108)
• Stewart G, Tazzyman ST, Lath D, Down J, Lawson M, Muthana M & Chantry A (2019) Myeloma-specific oncolytic adenovirus induces significant tumour oncolysis in vitro and in vivo and prevents cell line regrowth. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 185 (pp 97-97)
• Paton-Hough J, Lawson M & Chantry A (2019) Preventing and repairing myeloma bone disease by combining zoledronic acid with TGF beta inhibition therapy. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 185 (pp 16-16)
• Tattersall L, De Marchi E, Williamson A, Di VF, Lawson MA, Adinolfi E & Gartland A (2018) P2X7R in primary bone cancer. PURINERGIC SIGNALLING, Vol. 14 (pp S13-S14)
• Jiang Y, Down J, Raffles S, Jenkins E, Ferretti L, Bunce C, Drayson M, Lawson M & Khanim F (2018) Targeting free light chain (FLC) secretion and the unfolded protein response in myeloma cells using VaN, a combination of repurposed drugs. Experimental Hematology, Vol. 64(Suppl) (pp S74-S75). Los Angeles, USA, 23 August 2018 - 26 August 2018. View this article in WRRO
• Müller LME, Parrish C, Migneco G, Scott GB, Holmes M, Melcher AA, Lawson MA, Cook G & Errington-Mais F (2017) Abstract 18: Evaluating the contribution of anti-myeloma immunity for the efficacy of oncolytic reovirus therapy (pp 18-18)
• Mueller LME, Parrish C, Migneco G, Scott GB, Holmes M, Melcher AA, Lawson MA, Cook G & Errington-Mais F (2017) Evaluating the contribution of anti-myeloma immunity for the efficacy of oncolytic reovirus therapy.. CLINICAL CANCER RESEARCH, Vol. 23(24) (pp 44-44) View this article in WRRO
• Williams AJ, Lawson MA, Alamer O, Hough J, Bos T, Vanderkerken K & Croucher PI (2011) Multiphoton imaging of individual myeloma cells in calvariae: Association of myeloma development with sites of bone turnover. BONE, Vol. 48(1) (pp S14-S14)
• Vitovski S, Chantry AD, Lawson MA & Croucher PI (2011) Targeting tumour-initiating cells with trail based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo. BONE, Vol. 48(1) (pp S15-S15)
• Williams A, Lawson M, Bos T, Amani E, Hough J, Evans H, Lath D, Gallagher O, Coulton L, Vanderkerken K & Croucher P (2010) Imaging and quantitation of multiple myeloma in calvariae. BONE, Vol. 47 (pp S328-S328)
• Buckle CH, De Leenheer E, Lawson MA, Hough JM, Yong KL, Rabin N, Vanderkerken K & Croucher PI (2009) Soluble RANK ligand produced by myeloma cells contributes to generalised bone loss in multiple myeloma. BONE, Vol. 44 (pp S162-S162)
• Lawson MA, Williams AJ, Bos T, Vanderkerken K & Croucher PI (2009) Localising individual myeloma cells to the myeloma 'niche' in bone using multiphoton microscopy. BONE, Vol. 44 (pp S164-S164)
• Xia Z, Dunford J, Lawson MA, Triffitt JT, Kavanagh K, Oppermann U, Barnett BL, Ebetino FH & Russell RGG (2007) Nitrogen-containing bisphosphonates and prediction of their clinical potencies: Dissociation of target enzyme- and hydroxyapatite-binding affinities. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22(7) (pp 1125-1125)
• Xia Z, Dunford J, Lawson MA, Triffitt JT, Kavanagh K, Oppermann U, Roze C, Kashemirov B, McKenna CE, Ebetino FH & Russell RG (2007) Predicting pharmacological potencies of nitrogen-containing bisphosphonates; novel methods dissociate enzyme- and hydroxyapatite-binding affinities. BONE, Vol. 40(6) (pp S301-S302)
• Xia Z, Dunford J, Lawson MA, Triffitt JT, Barnett BL, Ebetino FH & Russell RGG (2007) Predicting the clinical potencies of bisphosphonates: Divergence of hydroxyapatite and farnesyl diphosphate synthase binding affinities. CALCIFIED TISSUE INTERNATIONAL, Vol. 80 (pp S155-S155)
• Lawson MA, Coulton L, Ebetino FH, Gallagher O, Prideaux M, Vanderkerken K & Croucher PI (2006) Risedronate prevents bone disease and reduces turnour burden in a syngeneic model of multiple myeloma.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21 (pp S137-S137)
• Xia Z, Dunford J, Lawson MA, Triffitt JT, Barnett BL, Roze C, Kashemirov B, McKenna CE, Ebetino FH & Russell RGG (2006) Refining structure activity relationships among nitrogen containing bisphosphonates: Dissociation of mineral binding affinity and inhibitory potency on farnesyl diphosphate synthase.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21 (pp S183-S183)
• Xia Z, Lawson MA, Triffitt JT, Ebetino FH, McKenna CE, Marma M, Kashemirov B & Russell RGG (2006) A novel method to characterize relative mineral binding affinities of bisphosphonates and the structural requirements for binding by using ceramic hydroxyapatite column chromatography.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21 (pp S191-S191)
• Lawson MA, Coulton L, Ebetino FH, Gallagher O, Prideaux M, Vanderkerken K & Croucher PI (2006) Risedronate prevents bone disease and reduces tumour burden in a syngeneic model of multiple myeloma. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21(7) (pp 1160-1160)
• Xia ZT, Triffitt JT, Lawson MA, Ebetino H, McKenna CE, Marma M, Kashimirov B & Russell RGG (2006) Substitutions in the R1 hydroxyl and C1 phosphate positions significantly affect binding of risedronate during hydroxyapatite ceramic chromatography. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21(7) (pp 1168-1168)
• Lawson MA, Coulton L, Ebetino FH, Gallagher O, Prideaux M, Vanderkerken K & Croucher P (2006) Risedronate prevents bone disease and reduces tumour burden in a syngeneic model of multiple myeloma. CANCER TREATMENT REVIEWS, Vol. 32 (pp S35-S35)
• Lawson MA, Triffitt JT, Ebetino FH, Barnett BL, Phipps RJ, Locklin RM & Russell RGG (2005) Potential bone mineral binding differences among bisphosphonates can be demonstrated by the use of hydroxyapatite column chromatography.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20(9) (pp S396-S396)
• Lawson MA, Triffitt JT, Ebetino FH, Barnett BL, Phipps RJ, White DJ & Russell RGG (2005) Differences in the potential binding of phosphate containing compounds to bone mineral are revealed by the novel use of hydroxyapatite column chromatography. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20(7) (pp 1303-1303)
• Lawson MA, Triffitt JT, Ebetino FH, Phipps RJ, White DJ & Russell RGG (2005) The use of hydroxyapatite column chromatography as a novel method to reveal differences in relative binding affinities of bisphosphonates. BONE, Vol. 36 (pp S308-S309)
• Wang L, Barralet JE, Lawson M, Triffitt JT, Cooper PC & Shelton RM (2004) Comparison of 2D and 3D bone marrow cell growth on alginate hydrogels. Transactions - 7th World Biomaterials Congress (pp 154)
• Lawson MA, Wang L, Shelton RM, Barralet JE & Triffitt JT (2004) Behaviour of bone marrow stromal cells on and within alginate gels for potential use in tissue engineering procedures. Transactions - 7th World Biomaterials Congress (pp 913)

Preprints

• Jiang Y, Down JM, Maynard S, Jenkins S, Ferritti L, Beke F, Al-Hazmi B, Southam AD, Kvist J, Mirbahai L , Besse L et al (2023) A repurposed drug combination (VaN) inhibits free light chain secretion and triggers the terminal unfolded protein response (UPR) in multiple myeloma (MM), Research Square Platform LLC.
• Diaz-delCastillo M, Palasca O, Nemler TT, Thygesen DM, Chávez-Saldaña NA, Vázquez-Mora JA, Ponce Gomez LY, Jensen LJ, Evans H, Andrews RE , Mandal A et al (2022) Metastatic infiltration of nervous tissue and periosteal nerve sprouting in multiple myeloma induced bone pain, Cold Spring Harbor Laboratory.
• Tattersall L, Shah KM, Lath DL, Singh A, Down JM, De Marchi E, Williamson A, Di Virgilio F, Heymann D, Adinolfi E , Fraser WD et al () The P2RX7B splice variant modulates osteosarcoma cell behaviour and metastatic properties.